ABILIFY®

Drug Information Related Patent

Hold Company

OTSUKA

Learn More

Dosage and Administration

TABLET;ORAL

Specification

10MG; 15MG; 20MG; 30MG; 5MG; 2MG

Indication

ABILIFY® is indicated for the treatment of schizophrenia, bipolar I mania and mixed episodes, major depression, irritability associated with autism, and Tourette's disease.

Use

Instructions for Use

API

ARIPIPRAZOLE

API Structure

We Supply

ARIPIPRAZOLE

Note:

In-house Standard/EP/USP
Facility GMP
USMF/CDE/CEP

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
8017615	2024/6/16
8017615*PED	2024/12/16
8759350	2027/3/2
9125939	2026/7/28
9387182	2023/12/25

API Patent

Patent No	Expiration Date
8017615	2024/6/16
8017615*PED	2024/12/16

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION